By Agnese Cattaneo,Angelini Pharma
Copyright politico
Szaflaraski M (2014), “Social determinants of health in epilepsy”
TEHA on GBD 2021 Nervous System Disorders Collaborators (2024), “Global, regional, and national burden of disorders affecting the nervous system, 1990-2021: a systemic analysis for the Global Burden of Disease Study 2021,” 2025
World Health Organisation. Epilepsy. Signs and Symptoms. Available online here: https://www.who.int/news-room/fact-sheets/detail/epilepsy. (Accessed August 2025]
Fisher RS, et al. Epilepsia 2014;55: 475-482
IBE, ILAE, WHO (2011), “Epilepsy in the WHO European Region.” and European Parliament (2011), “Proceedings of the workshop ‘Treating and living with Epilepsy’”
Thurman DJ et al. (2014), “The burden of premature mortality of epilepsy in high-income countries: A systematic review from the Mortality Task Force of the International League Against Epilepsy”. Epilepsia.
TEHA on Begley C et al. (2022), “The global cost of epilepsy: A systematic review and extrapolation”, Strzelczyk et al. (2015), “Costs of epilepsy and cost‐driving factors in children, adolescents, and their caregivers in Germany”, and Willems LM et al. (2021), “Multicenter, cross-sectional study of the costs of illness andcost-driving factors in adult patients with epilepsy”, 2025
Kwon C et al. (2022), “The worldwide epilepsy treatment gap: A systematic review and recommendations for revised definitions – A report from the ILAE Epidemiology Commission”. Epilepsia.
De Zélicourt M et al. (2014), “Management of focal epilepsy in adults treated with polytherapy in France: The direct cost of drug resistance (ESPERA study)”. Seizure.
Willems LM et al. (2022), “Multicenter, cross-sectional study of the costs of illness and cost-driving factors in adult patients with epilepsy”. Epilepsia
Dewhurst E et al. (2015), “A prospective service evaluation of acceptance and commitment therapy for patients with refractory epilepsy”. Epilepsy & Behavior.
TEHA Group elaboration on OECD data and Fleishman JA et al. (2006), “Using the SF-12 health status measure to improve predictions of medical expenditures”. Medical Care
The European House of Ambrosetti and Angelini Pharma. (2025) Brain Health in Uncertain Times: A strategic investment for Europe’s future
